Nephrogenic Diabetes Insipidus following an Off-Label Administration of Sevoflurane for Prolonged Sedation in a COVID-19 Patient and Possible Influence on Aquaporin-2 Renal Expression
During the recent COVID-19 pandemic, the rapidly progressive shortage of intravenous sedative drugs led numerous intensive care units to look for potential alternatives in patients requiring mechanical ventilation for severe acute respiratory distress syndrome (ARDS). Inhalational sedation using the...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | Case Reports in Anesthesiology |
| Online Access: | http://dx.doi.org/10.1155/2022/3312306 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850219853707739136 |
|---|---|
| author | Camie Dupuis Arnaud Robert Ludovic Gerard Johann Morelle Pierre-François Laterre Philippe Hantson |
| author_facet | Camie Dupuis Arnaud Robert Ludovic Gerard Johann Morelle Pierre-François Laterre Philippe Hantson |
| author_sort | Camie Dupuis |
| collection | DOAJ |
| description | During the recent COVID-19 pandemic, the rapidly progressive shortage of intravenous sedative drugs led numerous intensive care units to look for potential alternatives in patients requiring mechanical ventilation for severe acute respiratory distress syndrome (ARDS). Inhalational sedation using the AnaConDa® device for sevoflurane administration is a possible option. In a 54-year-old COVID-19 patient with severe ARDS requiring extracorporeal membranous oxygenation (ECMO), sevoflurane on AnaConDa® device was administered for 8 days but was complicated by the development of nephrogenic diabetes insipidus (NDI). Other causes of NDI or central diabetes insipidus were reasonably excluded, as in other previously published cases of NDI in ICU patients receiving prolonged sevoflurane-based sedation. In addition, the postmortem examination suggested a lower expression of aquaporin-2 in renal tubules. This observation should prompt further investigations to elucidate the role of aquaporin-2 in sevoflurane-related NDI. Inhaled isoflurane sedation is a possible alternative. |
| format | Article |
| id | doaj-art-76569bcf3e6a4473ac67e39d9fb06fac |
| institution | OA Journals |
| issn | 2090-6390 |
| language | English |
| publishDate | 2022-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Anesthesiology |
| spelling | doaj-art-76569bcf3e6a4473ac67e39d9fb06fac2025-08-20T02:07:16ZengWileyCase Reports in Anesthesiology2090-63902022-01-01202210.1155/2022/3312306Nephrogenic Diabetes Insipidus following an Off-Label Administration of Sevoflurane for Prolonged Sedation in a COVID-19 Patient and Possible Influence on Aquaporin-2 Renal ExpressionCamie Dupuis0Arnaud Robert1Ludovic Gerard2Johann Morelle3Pierre-François Laterre4Philippe Hantson5Department of Intensive CareDepartment of Intensive CareDepartment of Intensive CareDivision of NephrologyDepartment of Intensive CareDepartment of Intensive CareDuring the recent COVID-19 pandemic, the rapidly progressive shortage of intravenous sedative drugs led numerous intensive care units to look for potential alternatives in patients requiring mechanical ventilation for severe acute respiratory distress syndrome (ARDS). Inhalational sedation using the AnaConDa® device for sevoflurane administration is a possible option. In a 54-year-old COVID-19 patient with severe ARDS requiring extracorporeal membranous oxygenation (ECMO), sevoflurane on AnaConDa® device was administered for 8 days but was complicated by the development of nephrogenic diabetes insipidus (NDI). Other causes of NDI or central diabetes insipidus were reasonably excluded, as in other previously published cases of NDI in ICU patients receiving prolonged sevoflurane-based sedation. In addition, the postmortem examination suggested a lower expression of aquaporin-2 in renal tubules. This observation should prompt further investigations to elucidate the role of aquaporin-2 in sevoflurane-related NDI. Inhaled isoflurane sedation is a possible alternative.http://dx.doi.org/10.1155/2022/3312306 |
| spellingShingle | Camie Dupuis Arnaud Robert Ludovic Gerard Johann Morelle Pierre-François Laterre Philippe Hantson Nephrogenic Diabetes Insipidus following an Off-Label Administration of Sevoflurane for Prolonged Sedation in a COVID-19 Patient and Possible Influence on Aquaporin-2 Renal Expression Case Reports in Anesthesiology |
| title | Nephrogenic Diabetes Insipidus following an Off-Label Administration of Sevoflurane for Prolonged Sedation in a COVID-19 Patient and Possible Influence on Aquaporin-2 Renal Expression |
| title_full | Nephrogenic Diabetes Insipidus following an Off-Label Administration of Sevoflurane for Prolonged Sedation in a COVID-19 Patient and Possible Influence on Aquaporin-2 Renal Expression |
| title_fullStr | Nephrogenic Diabetes Insipidus following an Off-Label Administration of Sevoflurane for Prolonged Sedation in a COVID-19 Patient and Possible Influence on Aquaporin-2 Renal Expression |
| title_full_unstemmed | Nephrogenic Diabetes Insipidus following an Off-Label Administration of Sevoflurane for Prolonged Sedation in a COVID-19 Patient and Possible Influence on Aquaporin-2 Renal Expression |
| title_short | Nephrogenic Diabetes Insipidus following an Off-Label Administration of Sevoflurane for Prolonged Sedation in a COVID-19 Patient and Possible Influence on Aquaporin-2 Renal Expression |
| title_sort | nephrogenic diabetes insipidus following an off label administration of sevoflurane for prolonged sedation in a covid 19 patient and possible influence on aquaporin 2 renal expression |
| url | http://dx.doi.org/10.1155/2022/3312306 |
| work_keys_str_mv | AT camiedupuis nephrogenicdiabetesinsipidusfollowinganofflabeladministrationofsevofluraneforprolongedsedationinacovid19patientandpossibleinfluenceonaquaporin2renalexpression AT arnaudrobert nephrogenicdiabetesinsipidusfollowinganofflabeladministrationofsevofluraneforprolongedsedationinacovid19patientandpossibleinfluenceonaquaporin2renalexpression AT ludovicgerard nephrogenicdiabetesinsipidusfollowinganofflabeladministrationofsevofluraneforprolongedsedationinacovid19patientandpossibleinfluenceonaquaporin2renalexpression AT johannmorelle nephrogenicdiabetesinsipidusfollowinganofflabeladministrationofsevofluraneforprolongedsedationinacovid19patientandpossibleinfluenceonaquaporin2renalexpression AT pierrefrancoislaterre nephrogenicdiabetesinsipidusfollowinganofflabeladministrationofsevofluraneforprolongedsedationinacovid19patientandpossibleinfluenceonaquaporin2renalexpression AT philippehantson nephrogenicdiabetesinsipidusfollowinganofflabeladministrationofsevofluraneforprolongedsedationinacovid19patientandpossibleinfluenceonaquaporin2renalexpression |